The Multiple Faces of Prostaglandin E2 G-Protein Coupled Receptor Signaling during the Dendritic Cell Life Cycle

Abstract

Many processes regulating immune responses are initiated by G-protein coupled receptors (GPCRs) and report biochemical changes in the microenvironment. Dendritic cells (DCs) are the most potent antigen-presenting cells and crucial for the regulation of innate and adaptive immune responses. The lipid mediator Prostaglandin E2 (PGE2) via four GPCR subtypes (EP1-4) critically regulates DC generation, maturation and migration. The role of PGE₂ signaling in DC biology was unraveled by the characterization of EP receptor subtype expression in DC progenitor cells and DCs, the identification of the signaling pathways initiated by these GPCR subtypes and the classification of DC responses to PGE₂ at different stages of differentiation. Here, we review the advances in PGE₂ signaling in DCs and describe the efforts still to be made to understand the spatio-temporal fine-tuning of PGE₂ responses by DCs.

1. G-Protein-Coupled Receptor Signaling

The ability of cells to communicate with and respond to their external environment is critical for their survival and function. G-protein-coupled receptors (GPCRs) constitute a large and diverse family of proteins, which are crucial intermediates in the transmission and translation of extracellular information into intracellular responses [1]. The GPCR signaling cascade starts by binding a ligand to its receptor, thereby activating downstream signaling pathways, which finally result in complex cellular responses. The signaling and trafficking properties of GPCRs are often highly malleable depending on the cellular context. Receptor-interacting proteins that are differentially expressed in distinct cell types can attribute such plasticity of GPCR function. In addition, the spatiotemporal fine-tuning of a cell’s response to extracellular signals also depends on the probability of interaction between the receptor and its interaction partners, and this is controlled by the organization and lateral mobility of the signaling components within the plasma membrane [2–7]. Mechanisms exist that can control receptor localization and mobility, such as compartmentalization caused by cytoskeletal contacts, lipid environment or protein-protein interactions. Unraveling the mechanisms controlling GPCR signaling may lead to novel therapeutic approaches for treating diseases since GPCRs are amenable drug targets.

1.1. Immune Regulation by Dendritic Cells

Immune diseases and cancer are caused by a derailed or ineffective immune system. Understanding the molecular mechanisms that shape an effective immune response is a fundamental question in biology and essential towards the development of novel therapeutics.

Immune responses are orchestrated by a diverse group of functionally specialized, highly differentiated hematopoietic cell lineages. Dendritic cells (DCs) are the most effective antigen (Ag) presenting cells that play a central role in the induction of T-cell-mediated immunity [8]. In addition to activating the immune response, DCs are also decisive in creating tolerance. The pathway that is activated depends on the final balance between incoming signals [9]. In response to antigen uptake and exposure to inflammatory stimuli, DCs undergo a dramatic phenotypic conversion from a tissue resident, Ag-capturing cell to a highly migratory Ag-presenting cell, a process known as DC maturation. Activated DCs run an intricate migration track throughout the body involving the migration from peripheral tissues towards and their entry into the lymphatic vessels, as well as their final positioning in T-cell areas within the lymph nodes where they stimulate naïve T cells and initiate immune responses [8]. DCs are being exploited in the clinic for boosting immunological responses against various cancers by vaccination of cancer patients with ex vivo-generated autologous DC loaded with tumor antigens. However, although immunological responses are observed in most studies, clinical responses are limited to a minority of patients. The success of DC-based immunotherapy in inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of the Ag-loaded DC to T-cell-rich areas of secondary lymphoid tissues [10,11]. Therefore, in order to improve the clinical outcome, it is of the utmost importance to understand the molecular mechanisms that regulate the differentiation, maturation and migration of DC in order to optimize and steer the immune-regulatory capacities of ex vivo-generated DCs.

While extensive research addresses the role of chemokines and cytokines in DC function [12], only recently the role of lipid mediators in DC differentiation and function has been highlighted, when their indispensable role in the DC lifecycle became clear [13–16]. DC differentiation from hematopoietic stem cells (HSCs) and DC function are sensitive to sources of lipid mediators, such as prostaglandins, and DCs express several receptors involved in prostaglandin signaling pathways [17]. Prostaglandin E2 (PGE₂) is a key modulator of DC differentiation from their specific progenitor cells [18], DC maturation, migration and production of cytokines to influence T cell differentiation [19–22]. Depending on the site of encounter and the maturation stage, PGE₂ acts both as an immunoactivator and as an immunosuppressor in DCs, exerting a stimulatory function for immature DCs in peripheral tissues [19], and an inhibitory function for mature DCs in the lymph nodes [23]. Finally, PGE₂ differentially regulates cytokine production by DCs as a response to the context and changes in the microenvironment [22,24,25].

1.2. PGE₂ Signaling

The lipid mediator PGE₂ is a cyclooxygenase (COX) metabolite of arachidonic acid and exhibits the most versatile actions in a wide variety of tissues, modulating various pathological and physiological activities, such as cancer, fever, inflammation, atherosclerosis, blood pressure, stroke, and reproduction [26,27]. Arachidonic acid is modified by the constitutively active COX-1 and the inducible COX-2 producing prostaglandin H, which is further converted by three different PGE synthases, a cytosolic PGE synthases (cPGES) and two membrane bound PGE synthases (mPGES1 and mPGES2). cPGES and mPGES2 are constitutive active, whereas mPGES1 is inducible [28]. Finally, PGE₂ is degraded by 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the hydroxyl group is oxidized into 15-keto metabolites which exhibit greatly reduced biological activities [29,30].

PGE₂ biological actions have been attributed to its interactions with specific GPCRs localized at the plasma membrane [17]. PGE₂ is believed to act in an autocrine and a paracrine manner via a family of four cell surface or nuclear membrane GPCRs termed EP1–EP4, with distinctive signaling pathways [31]. EP1 is coupled to Gαq/p and activates phosphoinositide-phospholipase C (PLC), which ultimately leads to an increase in intracellular Ca²⁺[32]. EP2 and EP4 are coupled to the stimulatory Gαs, which leads to an increase in intracellular adenosine-3′,5′-cyclic monophosphate (cyclic adenosine monophosphate or cAMP) upon activation. Additionally EP4 has been described to be coupled to a Pertussis toxin-sensitive inhibitory G-protein, Gαi [33]. This will be discussed in more detail in the next paragraph. EP3 exists in three isoforms, all activating Gαi, which decrease cAMP production. Mouse studies suggest that the activation of these receptors induce multiple physiological functions: for example it mediates stress responses [34,35], it facilitates ovulation and fertilization [36], it regulates duodenal secretion [37] and it induces bone formation [38]. The specificity and diversity of PGE₂ effects can be explained by the local PGE₂ concentration due to the balance between its COX2-regulated synthesis and 15-PGDH-driven degradation, along with the characteristic expression pattern of different EP receptors with distinctive signaling mechanisms.

PGE₂ stimulates a broad spectrum of responses throughout most immune cells as reviewed in [39]. For example, PGE₂ selectively suppresses effector functions of macrophages and neutrophils and the Th1-, CTL-, and NK cell-mediated type 1 immunity at micromolar concentrations and stimulates Th1 and Th17 at nanomolar concentrations [40]. In addition, PGE₂ supports differentiation, maturation and migration of DCs but suppresses their ability to attract naive, memory, and effector T cells. PGE₂ regulates the immune response towards Th2 and Th17 immunity and enhances the local accumulation of regulatory T cells and myeloid-derived suppressor cells [41,42].

Dependent on DC subtype and species (human or mouse), DCs were shown to express either EP2 and EP4 or all four EP receptors, however PGE₂ exerts its effects only via EP2 and EP4 (Figure 1) [19,21,26,43,44]. The distinguishing feature of the EP2 and EP4 receptors is that their signaling is predominantly transduced by Gα_s, through which receptor activation is associated with an increase in adenylate cyclase activity and subsequently elevated intracellular cAMP levels [45,46]. However, EP4 ligation induces a weaker stimulation of intracellular cAMP when compared to the ligation of EP2 expressed at similar levels, although EP4 is known to have a higher affinity for PGE₂[47]. The production of cAMP and subsequently protein kinase A (PKA) leads to the phosphorylation of glycogen synthase kinase-3 (GSK-3) stimulating Tcf/Lef transcriptional activity. However, although EP4 is able to activate this signaling pathway, EP4 primarily induces Tcf/Lef transcriptional activity via a phosphatidyl-inositol 3 kinase (PI3K)-dependent pathway [48] through activation of Gαi [33,49]. In addition, EP2 and EP4 differentially regulate the PGE₂-mediated phosphorylation of the cAMP response element–binding protein (CREB), central to the regulation of cAMP responsive gene expression: EP2 stimulates the PKA- and EP4 mainly the PI3K-dependent pathway [50]. In contrast to EP2, EP4 induces the functional expression of early growth response factor-1 (EGR-1) via the PI3K/MAPK signaling pathway [47], which can result in the expression of PGE₂ synthase [51]. This can act as a positive feedback loop in which ligation of EP4 by PGE₂ leads to an increase in PGE₂ production via PGE₂ synthase. Another distinguishing feature of EP4 is its ligand-induced desensitization and internalization [48,52], depending on elements present in the carboxyl terminus of EP4. The carboxyl terminus of EP4 also contains sites for potential phosphorylation by G-protein coupled receptor kinases (GRK) [53], and arrestin-2 binding promotes EP4 internalization [54]. However, so far mutation of multiple potential GRK phosphorylation sites did not alter agonist-induced internalization [55], suggesting a different or more complex arrestin-EP4 binding mechanism [54]. EP2 has a much shorter C-tail than EP4, which could be a possible explanation for its desensitization- and internalization resistance and lack of arrestin-2 binding. Indeed, an arrestin mutant that binds and desensitizes regardless of phosphorylation status of the receptor did promote EP2 internalization and attenuate EP2 receptor signaling [54].

1.3. PGE₂ and Hematopoiesis

PGE₂ has a prominent role in controlling the number of hematopoietic stem cells (HSCs) from the bone marrow [56,57], but also HSC present in cord blood [58]. Although all four PGE₂ receptors were expressed in HSC at protein as well as at mRNA level [59], in the hematopoietic system only EP4 seems operative as recently shown [60]. In vitro exposure of HSCs to PGE₂ leads to better homing, survival and proliferation. The exposure of HSCs has profound influences on the enhanced expression of the C-X-C chemokine receptor type 4 (CXCR4) and survivin while the activity of caspase-3 is down-regulated, both processes inhibit apoptosis [61]. The CXCR4 receptor enhances the migration to stromal cell-derived factor-1 (SDF-1) in vitro and homing to the bone marrow in vivo[59]. Treatment in vitro and in vivo of HSC with PGE₂ results in an increase in stem cell numbers [57]. Dissecting the identity of the responding HSC showed that long term HSCs were unaffected by PGE₂ and that the increase in HSC number was due to an expansion of the short term HSCs [62]. The latter HSC has less renewal capacity. Presently it is unknown if the long term HSC lacks the receptors for PGE₂ or whether other downstream processes are modified. PGE₂ signaling raises the level of β-catenin that is part of the Wnt signaling pathway that drives hematopoiesis [63]. The link between PGE₂ and Wnt was pinpointed at LGR5, a molecule expressed by (cancer) stem cells and a Wnt target. The level of expression of LGR5 was upregulated by PGE₂[64]. Recently, it was shown that the upregulation of β-catenin is modulated via EP4 only [60]. Furthermore, PGE₂ appears to have a dual effect by stimulating the HSC but also the HSC supporting niche, again via the EP4 receptor [60].

After a massive expansion step, HSC differentiate into the eight different blood cell types. Most of these blood cells are insensitive to PGE₂ since blocking of PGE₂ production does not influence the differentiation of T cells, B cells and NK cells. In contrast, the number of monocytes increases and the number of DCs decreases after blocking PGE₂ synthesis with indomethacin [18]. Optimal development of DCs is regulated by PGE₂ via the EP1 and EP3 receptor. Triggering increases the receptor for Flt3, which is an important cytokine in DC development [60]. Thus, PGE₂ has regulatory properties on several stages of development of the hematopoietic system, these modulating effects being mediated by different receptor expression patterns.

1.4. PGE₂ Responses in Dendritic Cells

Various studies have demonstrated a multifaceted response of DCs to PGE₂. In particular, it recently became clear that the timing and extent of DC exposure to this lipid determine different cellular outcomes. Ex vivo, DCs can be generated through differentiation of peripheral blood monocytes in the presence of interleukin-4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) [65,66]. These moDCs are a well-established system to study DCs and they are currently also exploited in several anti-tumor clinical trials [10,67]. Differentiation of inflammatory monocytes into DCs has been shown to also occur in vivo[68], thus making the moDCs a valid model cell system.

The generation of DCs from peripheral blood monocytes has been shown to be inhibited in the presence of PGE₂, either exogenously added or secreted by co-cultured mesenchymal stem cells [69]. More recently, Kalinski and colleagues demonstrated that a positive feedback loop between PGE₂ and its synthesizing enzyme COX2 is able to redirect the differentiation of monocyte cultures towards stable myeloid-derived suppressor cells, which have opposing role in the immune system as compared to DCs [70]. In contrast to its inhibitory effects on monocytes, PGE₂ exhibits an activating function on the immature moDCs. In fact, PGE₂ is a key regulator of DC maturation, in particular responsible for the acquisition of a migratory phenotype. As a first step towards the transition from an adhesive to a highly migratory state, DCs dissolve specific integrin- and actin-rich adhesive structures called podosomes within minutes after PGE₂ stimulation [20,71]. This fast response to PGE₂ is mediated by elevation of cAMP intracellular levels, activation of the small GTPase RhoA and subsequent induction of actomyosin contraction ultimately leading to fast podosome dissolution [21]. Combined with proinflammatory cytokines, PGE₂ specifically upregulates the surface expression levels of the chemokine receptor CCR7, which is responsible for the chemotactic responsiveness of DCs to lymph node-derived chemokines such as CCL19 and CCL21 [72]. Furthermore, prolonged incubation of DCs with PGE₂ induces expression of matrix metalloproteinase 9 (MMP-9), which together with CCR7 is responsible for the directional migration of DCs to draining lymph nodes [73,74]. It should be noted that to enable DC chemotaxis, PGE₂ addition is absolutely required at early time points of maturation, as addition of PGE₂ during terminal maturation stages is no longer effective [19].

Besides stimulating DC migration, PGE₂ plays also a role in enhancing the T cell stimulatory capacity of DCs by inducing the upregulation of costimulatory receptors such as OX40L, CD70 and 4-1BBL early during DC maturation that results in an increased capacity to induce proliferation of CD4+ and CD8+ T cells [75], despite the concomitant induction of several suppressive factors like thrombospondin-1 [76] and IDO [77], known to suppress T cell proliferation and survival promoting tolerance. In addition, DC function is influenced by the production of specific cytokines. PGE₂ induces IL-10 production, a known inhibitor of DC maturation [78] and suppresses the production of IL-12, shifting the balance from a Th1 to a Th2 response [79,80]. A very recent study by Woodward and colleagues demonstrated that PGE₂ can differentially regulate DC production of cytokines depending on the EP receptor that is stimulated [81]. For example, low concentrations (up to 10 nM) of PGE₂ appear to stimulate the Th17 response supporting IL-23 release via EP4 [82], whereas at concentrations higher than 50 nM PGE₂ inhibits IL-23 production in an EP2 dependent manner [81]. These novel findings indicate that subtle changes in PGE₂ concentration in the extracellular microenvironment can specifically activate one particular receptor thus differentially modulating cellular responses.

Interestingly, the effects of PGE₂ on naturally occurring DC subsets seem to be quite diverse. For example, signaling of PGE₂ through EP4 was found to facilitate the initiation of skin immune responses by enhancing maturation and migration of Langerhans cells [43]. In contrast, on human plasmacytoid DCs (pDCs) PGE₂ has been shown to potently inhibit secretion of IFN-alpha by pDCs upon stimulation with Toll-like receptor ligands, with subsequent decreased secretion of Th1 cytokines by co-cultured T cells [83]. PGE₂ inhibits IFN-alpha secretion and Th1 costimulation by human pDCs via EP2 and EP4 engagement [84]. PGE₂ can therefore be considered as a negative regulator on human pDCs [85]. Considering the large variety of properties and functions of the various DC subsets, might lead to multiple cellular responses. This once again highlights the complexity and multifaceted action of PGE₂ signaling in DCs.

2. Outlook

PGE₂ acts both as an immunosuppressor and an immunoactivator throughout the lifecycle of DCs (Figure 2). Therefore, knowledge on the complexity of PGE₂ signaling is necessary in order to predict, control and intervene in the PGE₂ response in experimental and possibly clinical settings. The different cellular effects mediated by PGE₂ in DCs marginally depend on the expression pattern of the EP receptors. Although differentiation of DCs seems regulated via EP1 and EP3, the function of DCs during their lifecycle is always regulated via EP2 and EP4. Therefore, the expression levels of EP2 and EP4, their different affinity for PGE₂ and the extent of activation of the different signaling pathways downstream of EP2 and EP4 will enable a DC to tune cellular outputs in response to PGE₂. The extent of EP2 and EP4 activity is critically dependent on the probability of interaction between the receptor and receptor-interacting proteins, like Gαs, Gαi and arrestin, and subjected to precise regulation of localization in time and space. Furthermore, cross talk of the EP2 and EP4 signaling pathways might occur as well as cross talk by different receptors, influencing the availability of receptor interacting partners or downstream signaling proteins. To fully understand PGE₂ regulated processes in DCs, all individual molecular interactions should be followed in space and time, which would allow us to build a dynamic and quantitative signaling network connectivity-map for prediction of the DC response to PGE₂ based on parameters like for example, receptor numbers, affinities etc. With the rapid development and improvement of high-resolution bioimaging techniques suited for the investigation of fast signal transduction processes at the molecular level [86], we expect to be able to simultaneously investigate multiple molecular interactions involved in the PGE₂ receptor signal cascade, which might represent a paradigm for other GPCR signaling pathways.